CP
MDGL icon

CenterBook Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

CenterBook Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-953
Closed -$221K – 448
2023
Q4 		$221K Sell
953
-17,074
-95% -$2.99M 0.03% 372
2023
Q3 		$2.63M Buy
+18,027
New +$3.39M 0.33% 92

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

CenterBook Partners's MDGL Position: Q1 2024 in Review

CenterBook Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2024, closing a stake of 953 shares — an estimated $221K sold.

CenterBook Partners first reported a position in MDGL in Q3 2023 and held it in 2 quarters. The position peaked at $2.63M in Q3 2023. 268 funds tracked by Wall St. Rank hold MDGL as of Q1 2024.

  • CenterBook Partners reported no remaining Madrigal Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • CenterBook Partners sold 953 Madrigal Pharmaceuticals shares in Q1 2024, an estimated $221K.
  • CenterBook Partners first reported a position in Madrigal Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • CenterBook Partners's Madrigal Pharmaceuticals position peaked at $2.63M in Q3 2023.
  • 268 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2024.

Based on CenterBook Partners's 13F filing for Q1 2024, filed 10 May 2024.